A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp.

Abstract excerpt

ABSTRACT In the ATTACK Phase 3 trial examining the efficacy of sulbactam (SUL)/durlobactam (DUR) to treat primarily Acinetobacter baumannii complex (ABC) infections, imipenem (IPM)/cilastatin was added as a common therapy to both the SUL/DUR and the comparator colistin arms. This raised the question of whether the use of IPM in the SUL/DUR arm of the study influenced the efficacy of SUL/DUR. To investigate this...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibiotic Resistance in Bacteria
• Share to Antibiotics Pharmacokinetics and Efficacy
• Share to Pneumonia and Respiratory Infections